Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement

Apr

15

Today In Oncology

Large Language Models May Generate Concise, Coherent Pathology Summaries, Reducing Physician Burden

PSMA PET-CT Scan Reduces Need for Prostate Cancer Biopsies

Surgery Still Safe Beneficial For Many Octogenarian Patients With NSCLC

Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors

NCCN Names New Chief Scientific Officer

Advertisement

© 2026 HSP News Service, L.L.C.